Microsatellite Instability, Epstein–Barr Virus, and Programmed Cell Death Ligand 1 as Predictive Markers for Immunotherapy in Gastric Cancer

Hung Yuan Yu; Chung Pin Li; Yi Hsiang Huang; Shao Jung Hsu; Yen Po Wang; Yun Cheng Hsieh; Wen Liang Fang; Kuo Hung Huang; Anna Fen Yau Li; Rheun Chuan Lee; Kang Lung Lee; Yuan Hung Wu; I. Chun Lai; Wan Chin Yang; Yi Ping Hung; Yu Chao Wang; Shu Hui Chen; Ming Huang Chen; Yee Chao

doi:10.3390/cancers14010218

Microsatellite Instability, Epstein–Barr Virus, and Programmed Cell Death Ligand 1 as Predictive Markers for Immunotherapy in Gastric Cancer

Hung Yuan Yu, Chung Pin Li, Yi Hsiang Huang, Shao Jung Hsu, Yen Po Wang, Yun Cheng Hsieh, Wen Liang Fang, Kuo Hung Huang, Anna Fen Yau Li, Rheun Chuan Lee, Kang Lung Lee, Yuan Hung Wu, I. Chun Lai, Wan Chin Yang, Yi Ping Hung, Yu Chao Wang, Shu Hui Chen, Ming Huang Chen^*, Yee Chao^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

18 Scopus citations

Abstract

Immunotherapy benefits selected cases of gastric cancer (GC), but the correlation between biomarkers and prognosis is still unclear. Fifty-two patients with GC who underwent immunother-apy were enrolled from June 2016 to December 2020. Their clinical features and biomarkers—mi-crosatellite instability-high (MSI-H), programmed cell death ligand 1 (PD-L1) combined positive score (CPS), and Epstein–Barr encoding region (EBER)—were analyzed. Eight patients had MSI-H, five patients had EBER, 29 patients had CPS ≥ 1, and 20 patients had no biomarker. The overall response rates (ORRs) of the MSI-H, EBER, PD-L1 CPS ≥ 1, and all-negative group were 75%, 60%, 44.8%, and 15%, respectively. Compared with that of the all-negative group, progression-free survival (PFS) was better in the MSI-H (p = 0.018), CPS ≥ 5 (p = 0.012), and CPS ≥ 10 (p = 0.006) groups, but not in the EBER (p = 0.2) and CPS ≥ 1 groups (p = 0.35). Ten patients had combined biomarkers, CPS ≥ 1 with either MSI-H or EBER. The ORRs were 66.7% for CPS ≥ 1 and MSI-H and 75% for CPS ≥ 1 and EBER. PFS was better in patients with combined biomarkers (p = 0.01). MSI-H, EBER, and CPS are useful biomarkers for predicting the efficacy of immunotherapy.

Original language	English
Article number	218
Journal	Cancers
Volume	14
Issue number	1
DOIs	https://doi.org/10.3390/cancers14010218
State	Published - 1 Jan 2022

Keywords

Epstein–Barr virus
Gastric cancer
Immunotherapy
Microsatellite instability
Programmed cell death ligand 1

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3390/cancers14010218

Cite this

Yu, H. Y., Li, C. P., Huang, Y. H., Hsu, S. J., Wang, Y. P., Hsieh, Y. C., Fang, W. L., Huang, K. H., Li, A. F. Y., Lee, R. C., Lee, K. L., Wu, Y. H., Lai, I. C., Yang, W. C., Hung, Y. P., Wang, Y. C., Chen, S. H., Chen, M. H., & Chao, Y. (2022). Microsatellite Instability, Epstein–Barr Virus, and Programmed Cell Death Ligand 1 as Predictive Markers for Immunotherapy in Gastric Cancer. Cancers, 14(1), Article 218. https://doi.org/10.3390/cancers14010218

@article{6f69d365cec44aea8433de521a1a69a0,

title = "Microsatellite Instability, Epstein–Barr Virus, and Programmed Cell Death Ligand 1 as Predictive Markers for Immunotherapy in Gastric Cancer",

abstract = "Immunotherapy benefits selected cases of gastric cancer (GC), but the correlation between biomarkers and prognosis is still unclear. Fifty-two patients with GC who underwent immunother-apy were enrolled from June 2016 to December 2020. Their clinical features and biomarkers—mi-crosatellite instability-high (MSI-H), programmed cell death ligand 1 (PD-L1) combined positive score (CPS), and Epstein–Barr encoding region (EBER)—were analyzed. Eight patients had MSI-H, five patients had EBER, 29 patients had CPS ≥ 1, and 20 patients had no biomarker. The overall response rates (ORRs) of the MSI-H, EBER, PD-L1 CPS ≥ 1, and all-negative group were 75%, 60%, 44.8%, and 15%, respectively. Compared with that of the all-negative group, progression-free survival (PFS) was better in the MSI-H (p = 0.018), CPS ≥ 5 (p = 0.012), and CPS ≥ 10 (p = 0.006) groups, but not in the EBER (p = 0.2) and CPS ≥ 1 groups (p = 0.35). Ten patients had combined biomarkers, CPS ≥ 1 with either MSI-H or EBER. The ORRs were 66.7% for CPS ≥ 1 and MSI-H and 75% for CPS ≥ 1 and EBER. PFS was better in patients with combined biomarkers (p = 0.01). MSI-H, EBER, and CPS are useful biomarkers for predicting the efficacy of immunotherapy.",

keywords = "Epstein–Barr virus, Gastric cancer, Immunotherapy, Microsatellite instability, Programmed cell death ligand 1",

author = "Yu, {Hung Yuan} and Li, {Chung Pin} and Huang, {Yi Hsiang} and Hsu, {Shao Jung} and Wang, {Yen Po} and Hsieh, {Yun Cheng} and Fang, {Wen Liang} and Huang, {Kuo Hung} and Li, {Anna Fen Yau} and Lee, {Rheun Chuan} and Lee, {Kang Lung} and Wu, {Yuan Hung} and Lai, {I. Chun} and Yang, {Wan Chin} and Hung, {Yi Ping} and Wang, {Yu Chao} and Chen, {Shu Hui} and Chen, {Ming Huang} and Yee Chao",

note = "Publisher Copyright: {\textcopyright} 2022 by the authors. Licensee MDPI, Basel, Switzerland.",

year = "2022",

month = jan,

day = "1",

doi = "10.3390/cancers14010218",

language = "English",

volume = "14",

journal = "Cancers",

issn = "2072-6694",

publisher = "Multidisciplinary Digital Publishing Institute",

number = "1",

}

Yu, HY, Li, CP, Huang, YH, Hsu, SJ, Wang, YP, Hsieh, YC, Fang, WL, Huang, KH, Li, AFY, Lee, RC, Lee, KL, Wu, YH, Lai, IC, Yang, WC, Hung, YP, Wang, YC, Chen, SH, Chen, MH & Chao, Y 2022, 'Microsatellite Instability, Epstein–Barr Virus, and Programmed Cell Death Ligand 1 as Predictive Markers for Immunotherapy in Gastric Cancer', Cancers, vol. 14, no. 1, 218. https://doi.org/10.3390/cancers14010218

TY - JOUR

T1 - Microsatellite Instability, Epstein–Barr Virus, and Programmed Cell Death Ligand 1 as Predictive Markers for Immunotherapy in Gastric Cancer

AU - Yu, Hung Yuan

AU - Li, Chung Pin

AU - Huang, Yi Hsiang

AU - Hsu, Shao Jung

AU - Wang, Yen Po

AU - Hsieh, Yun Cheng

AU - Fang, Wen Liang

AU - Huang, Kuo Hung

AU - Li, Anna Fen Yau

AU - Lee, Rheun Chuan

AU - Lee, Kang Lung

AU - Wu, Yuan Hung

AU - Lai, I. Chun

AU - Yang, Wan Chin

AU - Hung, Yi Ping

AU - Wang, Yu Chao

AU - Chen, Shu Hui

AU - Chen, Ming Huang

AU - Chao, Yee

PY - 2022/1/1

Y1 - 2022/1/1

N2 - Immunotherapy benefits selected cases of gastric cancer (GC), but the correlation between biomarkers and prognosis is still unclear. Fifty-two patients with GC who underwent immunother-apy were enrolled from June 2016 to December 2020. Their clinical features and biomarkers—mi-crosatellite instability-high (MSI-H), programmed cell death ligand 1 (PD-L1) combined positive score (CPS), and Epstein–Barr encoding region (EBER)—were analyzed. Eight patients had MSI-H, five patients had EBER, 29 patients had CPS ≥ 1, and 20 patients had no biomarker. The overall response rates (ORRs) of the MSI-H, EBER, PD-L1 CPS ≥ 1, and all-negative group were 75%, 60%, 44.8%, and 15%, respectively. Compared with that of the all-negative group, progression-free survival (PFS) was better in the MSI-H (p = 0.018), CPS ≥ 5 (p = 0.012), and CPS ≥ 10 (p = 0.006) groups, but not in the EBER (p = 0.2) and CPS ≥ 1 groups (p = 0.35). Ten patients had combined biomarkers, CPS ≥ 1 with either MSI-H or EBER. The ORRs were 66.7% for CPS ≥ 1 and MSI-H and 75% for CPS ≥ 1 and EBER. PFS was better in patients with combined biomarkers (p = 0.01). MSI-H, EBER, and CPS are useful biomarkers for predicting the efficacy of immunotherapy.

AB - Immunotherapy benefits selected cases of gastric cancer (GC), but the correlation between biomarkers and prognosis is still unclear. Fifty-two patients with GC who underwent immunother-apy were enrolled from June 2016 to December 2020. Their clinical features and biomarkers—mi-crosatellite instability-high (MSI-H), programmed cell death ligand 1 (PD-L1) combined positive score (CPS), and Epstein–Barr encoding region (EBER)—were analyzed. Eight patients had MSI-H, five patients had EBER, 29 patients had CPS ≥ 1, and 20 patients had no biomarker. The overall response rates (ORRs) of the MSI-H, EBER, PD-L1 CPS ≥ 1, and all-negative group were 75%, 60%, 44.8%, and 15%, respectively. Compared with that of the all-negative group, progression-free survival (PFS) was better in the MSI-H (p = 0.018), CPS ≥ 5 (p = 0.012), and CPS ≥ 10 (p = 0.006) groups, but not in the EBER (p = 0.2) and CPS ≥ 1 groups (p = 0.35). Ten patients had combined biomarkers, CPS ≥ 1 with either MSI-H or EBER. The ORRs were 66.7% for CPS ≥ 1 and MSI-H and 75% for CPS ≥ 1 and EBER. PFS was better in patients with combined biomarkers (p = 0.01). MSI-H, EBER, and CPS are useful biomarkers for predicting the efficacy of immunotherapy.

KW - Epstein–Barr virus

KW - Gastric cancer

KW - Immunotherapy

KW - Microsatellite instability

KW - Programmed cell death ligand 1

UR - http://www.scopus.com/inward/record.url?scp=85122108800&partnerID=8YFLogxK

U2 - 10.3390/cancers14010218

DO - 10.3390/cancers14010218

M3 - Article

AN - SCOPUS:85122108800

SN - 2072-6694

VL - 14

JO - Cancers

JF - Cancers

IS - 1

M1 - 218

ER -

Microsatellite Instability, Epstein–Barr Virus, and Programmed Cell Death Ligand 1 as Predictive Markers for Immunotherapy in Gastric Cancer

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this